
BioNTech SE
BioNTech SE (BNTX)
WebsitePrice
Market cap
Next catalystExpected 2026Pumitamig plus obrixtamig — planned ES-SCLC study · Trial initiationSEC filing ↗
Cash
Chart & Events
Core Clinical
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
Other pipelines
Partner / License out
Approved / commercial
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
History / paused
Financial position
Company funding outlook
Upcoming milestones
Financial history
Annual trends
| Reported item | |||||
|---|---|---|---|---|---|
Reported shares and borrowings
Ownership and institutions
| Status | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|